ALB and cancer: Since the first cancer nanomedicine, Doxil, was approved by the Food and Drug Administration (FDA) in 1995, there have been at least 17 kinds of cancer nanomedicine applied in the clinic, including Abraxane (albumin-bound paclitaxel), Oncaspar (PEGylated L-asparaginase), Genexol-PM (mPEG-PDLLA micellar paclitaxel), NanoTherm® AS1, etc. (Table 1).